ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosomes technologies, announces that the Company’s CSO, Dr Randolph Corteling, has presented new data at the Extracellular Vesicle-Based Therapeutic Development Summit in Boston, MA, highlighting the significant advantages of the Company’s stem cell derived exosome approach.